Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, ... Geography Trend and Forecast (2011 - 2016)," analyzes ... and studies the major market drivers, restraints, and opportunities ... Asia. , The global chocolate market is expected to ... 2016 at an estimated CAGR of 2.7% from 2011 ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... 21-1/2 hours of great entertainment and powerful appeals, the final ... Lewis MDA Telethon which raised $58,919,838 in contributions and ... Muscular Dystrophy Association.   "I,m heartened by the ... they themselves are likely struggling financially," said Lewis.  "People see ...
... COLUMBIA, Md., Sept. 3 The Maryland Stem Cell ... Stem Cell Research Symposium in partnership with the National ... Standards and Technology (NIST) on Wednesday, Sept. 22, 2010. ... Groundbreaking Life Science Research," will be held at the ...
... - 2015) -... -- DALLAS, Texas, September 3, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:MDA Telethon Exceeds Expectations 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 4New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 5New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 6New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 7New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 8
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
(Date:10/14/2014)... tumors scavenge and hoard copper that is an essential ... a fatal weakness. , Researchers at Duke Medicine ... by delivering a trove of copper along with a ... the mineral, leaving non-cancer cells healthy. , The combination ... other uses, could soon be tested in clinical trials ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... would overheat and die. In a recent paper in the journal ... team of researchers explored the ultimate origin of this sticky, stinky ... his team used a system to make all of the sweat ... green fluorescent protein (GFP), which is visible under ultraviolet light. ...
... the first evidence that coral itself may play an ... discovered that the coral animalnot just its algal symbiontmakes ... in many ways, ranging from cellular protection in times ... clouds to form. These findings have been published ...
... combination of the herbicide atrazine and a fungal disease ... a University of South Florida laboratory, which has been ... Biologist Jason Rohr said the new findings show that ... when the frogs were challenged with a chytrid fungus, ...
Cached Biology News:USC researcher learns how to break a sweat 2Coral chemicals protect against warming oceans 2Early-life exposure of frogs to herbicide increases mortality from fungal disease 2
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
Request Info...
... LXQ linear ion trap mass spectrometer enables ... laboratory., The LXQ linear ion trap mass ... proteomic applications, delivering the fast cycle time ... ion trap at an attractive price. ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: